Parkinson’s disease is one of the most severe progressive neurodegenerative disorders, having a mortifying
effect on the health of millions of people around the globe. The neural cells producing dopamine in the
substantia nigra of the brain die out. This leads to symptoms like hypokinesia, rigidity, bradykinesia, and rest
tremor. Parkinsonism cannot be cured, but the symptoms can be reduced with the intervention of medicinal drugs,
surgical treatments, and physical therapies. Delivering drugs to the brain for treating Parkinson’s disease is very
challenging. The blood-brain barrier acts as a highly selective semi-permeable barrier, which refrains the drug
from reaching the brain. Conventional drug delivery systems used for Parkinson’s disease do not readily cross the
blood barrier and further lead to several side-effects. Recent advancements in drug delivery technologies have
facilitated drug delivery to the brain without flooding the bloodstream and by directly targeting the neurons. In
the era of Nanotherapeutics, liposomes are an efficient drug delivery option for brain targeting. Liposomes
facilitate the passage of drugs across the blood-brain barrier, enhances the efficacy of the drugs, and minimize the
side effects related to it. The review aims at providing a broad updated view of the liposomes, which can be used
for targeting Parkinson’s disease.
Corrigendum to “Exosomes as drug delivery vehicles for Parkinson's disease therapy” [Journal of Controlled Release 207, (2015) 18–30]
